Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Illumina's ar-ray of sunshine

Once a little fish among array manufacturers, Illumina Inc. has become one of the leaders in the field of genetic tools. The company removed a potential obstacle to its continued growth last week, agreeing to pay $90 million to settle patent infringement litigation brought by Affymetrix Inc.

The companies are direct competitors in the genetic analysis marketplace, and have been litigating ever since Affymetrix filed suit in July 2004 alleging infringement

Read the full 715 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE